Page 8 - Aduhelm News Today

Biogen withdrew an application seeking approval in Europe for Alzheimer’s disease drug Aduhelm, a move that follows a negative opinion on the therapy issued by a European Medicines Commission committee last December. The company was unable to persuade European regulators to change their minds about the drug.

It’s not really a novel idea, requiring a drug to prove a benefit to patients before being covered by Medicare. But in Alzheimer’s disease, it’s been a massive debate.

The Freedom of Information Act (FOIA) request seeks materials regarding cost considerations, the FDA’s Accelerated Approval Program, and potential harm to...

Although Medicare has agreed to pay for Aduhelm, its coverage comes with restrictions.

Of the new cases, 1,318 were locally transmitted, the National Health Commission said, compared with 1,334 on April 8. Italy reports 53,253 coronavirus cases, 90 deaths on Sunday Italy reported 53,253 COVID-19 related cases on Sunday, down from 63,992 the day before, the health ministry said, while the number of deaths fell to 90 from 112.

Biogen’s Alzheimer’s disease drug Aduhelm will only be covered for Medicare beneficiaries participating in a clinical trial. The final coverage determination will have the effect of limiting use of the drug, but the agency said its decision provides clarity on what drug companies need to show in order to secure Medicare coverage.

Medicare will only cover a drug for Alzheimer's disease for patients in clinical trials, President Joe Biden's administration ...

WASHINGTON (AP) — Medicare said Thursday its considering a cut in enrollee premiums,...

Officials cited data showing the new Alzheimer’s drug has serious safety risks and may not help patients.

The Alzheimer’s Association has pushed relentlessly to get broad access to Aduhelm, despite safety risks and uncertain evidence that it helps patients.